BernagieC, DanckaertsM, WampersM, De HertM: Aripiprazole and acute extrapyramidal symptoms in children and adolescents: A meta-analysis. CNS Drugs, 30:807–818, 2016.
3.
Bevan JonesR, ThaparA, LewisG, ZammitS: The association between early autistic traits and psychotic experiences in adolescence. Schizophr Res, 135:164–169, 2012.
4.
DominoME, SwartzMS: Who are the new users of antipsychotic medications?. Psychiatr Serv, 59:507–514, 2008.
5.
FindlingRL, KauffmanRE, SalleeFR, CarsonWH, NyilasM, MallikaarjunS, et al.: Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study. J Clin Psychopharmacol, 28:441–446, 2008.
6.
GaoK, MuzinaD, GajwaniP, CalabreseJR: Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review. J Clin Psychiatry, 67:1327–1340, 2006.
7.
GarraldaME: Fifteen minute consultation on children “hearing voices”: When to worry and when to refer. Arch Dis Childhood Educ Pract Ed, 100:233–237, 2015.
8.
JohnsLC, NazrooJY, BebbingtonP, KuipersE: Occurrence of hallucinatory experiences in a community sample and ethnic variations. Br J Psychiatry, 180:174–178, 2011.
9.
KatzmanMA: Aripiprazole: A clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness. J Affect Disord, 128:S11–S20, 2011.
10.
KirinoE: Efficacy and safety of aripiprazole in child and adolescent patients. Eur Child Adolesc Psychiatry, 21:361–368, 2012.
11.
KotsopoulosS, KansibergJ, CoteA, FiedorowiczC: Hallucinatory experiences in nonpsychotic children. J Am Acad Child Adolesc Psychiatry, 26:375–380, 1987.
12.
MaijerK, PalmenSJMC, SommerIEC: Children seeking help for auditory verbal hallucinations; who are they?. Schizophr Res, 2016 [Epub ahead of print] DOI: 10.1016/j.schres.2016.10.033.
13.
MertinP, O'BrienN: High emotional arousal and failures in reality monitoring: Pathways to auditory hallucinations in non-psychotic children?. Scand J Psychol, 54:102–106, 2013.
14.
PringsheimT, DojaA, BelangerS, PattenS; Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) Guideline Group: Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatr Child Health, 16:590–598, 2011.
